NeoGenomics Analyst Price Targets - Benzinga

NeoGenomics Inc

NEONASDAQ

Trade with Public

Trade with Public

$19.13

0.663.57%

最終更新: Oct 5, 6:53 PM

$18.32

-0.15-0.81%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

NeoGenomics Analyst Price Targets - Benzinga

NeoGenomics Analyst Price Targets

Wall Street analyst price targets and consensus rating for NeoGenomics (NEO).

Price Target Range — 11 Quarters

Analyst Consensus — 12 Analysts

10Buy

2Hold

Consensus RatingBuy# Analysts12Avg. Consensus PT$16Upside to Avg. PT-11.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 29, 2026	Needham	Mike Matson	PT Raise	Buy	$15→$19
Jul 24, 2026	Benchmark	Bruce D. Jackson	PT Raise	Buy	$11→$16
Apr 29, 2026	Benchmark	Bruce Jackson	Upgrade	Hold→Buy	$11
Apr 29, 2026	TD Cowen	Dan Brennan	PT Raise	Buy	$13→$14
Apr 29, 2026	Leerink Partners	Puneet Souda	Upgrade	Market Perform→Outperform	$12→$25
Feb 24, 2026	Piper Sandler	David Westenberg	PT Raise	Overweight	$12→$13
Feb 17, 2026	Needham	Mike Matson	PT Raise	Buy	$14→$15
Jan 12, 2026	Needham	Mike Matson	Maintained	Buy	$14
Sep 12, 2025	TD Cowen	Dan Brennan	PT Raise	Buy	$10→$12
Sep 2, 2025	Stephens & Co.	Mason Carrico	PT Raise	Overweight	$7→$11
Aug 29, 2025	Needham	Mike Matson	PT Raise	Buy	$8→$14
Aug 4, 2025	Piper Sandler	David Westenberg	PT Cut	Overweight	$12→$11
Jul 30, 2025	Morgan Stanley	Tejas Savant	PT Cut	Equal-Weight	$10→$8
Jul 29, 2025	Needham	Mike Matson	PT Cut	Buy	$9→$8
Jul 29, 2025	William Blair	—	Downgrade	Outperform→Market Perform	—
May 6, 2025	Piper Sandler	David Westenberg	PT Cut	Overweight	$18→$12
May 1, 2025	Morgan Stanley	Tejas Savant	PT Cut	Equal-Weight	$17→$10
Apr 30, 2025	Goldman Sachs	Matthew Sykes	PT Cut	Buy	$15→$10
Apr 30, 2025	Leerink Partners	Puneet Souda	Downgrade	Outperform→Market Perform	$25→$9
Apr 29, 2025	Needham	Mike Matson	PT Cut	Buy	$18→$9

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Needham Maintains Buy on NeoGenomics, Raises Price Target to $19

Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $15 to $19.

Benzinga Newsdesk

PRO
Benchmark Maintains Buy on NeoGenomics, Raises Price Target to $16

Benchmark analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $11 to $16.

Benzinga Newsdesk

PRO
Benchmark Upgrades NeoGenomics to Buy, Announces $11 Price Target

Benchmark analyst Bruce Jackson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and announces $11 price target.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $14

TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $13 to $14.

Benzinga Newsdesk

PRO
Leerink Partners Upgrades NeoGenomics to Outperform, Raises Price Target to $25

Leerink Partners analyst Puneet Souda upgrades NeoGenomics (NASDAQ:NEO) from Market Perform to Outperform and raises the price target from $12 to $25.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on NeoGenomics, Raises Price Target to $13

Piper Sandler analyst David Westenberg maintains NeoGenomics (NASDAQ:NEO) with a Overweight and raises the price target from $12 to $13.

Benzinga Newsdesk